

Chemodivergent Synthesis of Aza-Heterocycles with a Quarternary Carbon Center via [4 + 1] Annulation between Azoalkenes and α -Bromo Carbonyl Compounds

Xiaoke Zhang,* Haibo Wang, Ziwei Li, Yan Shu, Song Gan, Xuefang Zhang, Huawu Shao, and Chaoyong Wang*



Cite This: *ACS Omega* 2022, 7, 40963–40972



Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: An efficient [4 + 1] annulation reaction between in situ generated azoalkene intermediates and α -bromocarbonyls has been established. A series of skeletally diverse aza-heterocycles with a functionalized quaternary center were obtained in up to 89% yield under mild conditions.



INTRODUCTION

Dihydropyrazole and indoline skeletons are privileged units and widely exist in a number of natural products with a broad spectrum of biological activities.¹ They have been employed as a receptor-interacting protein 1 kinase inhibitor, antibacterial agent, monoamine oxidase inhibitor, COX-2 inhibitor and acyl-CoA: cholesterol acyl-transferase (ACAT) inhibitor (Figure 1).² Thus, an array of methods for the construction of such compounds have been developed.³ However, these protocols are often plagued by the need for metal catalysis and a high reactive partner to obtain an indoline-2-carboxylic acid skeleton and 4,5-dihydropyrazole-containing ester functional group. For instance, indoline-2-carboxylic acid skeletons were obtained through reduction of an indole derivative and

cycloaddition reaction catalyzed by the metals Rh and Fe.^{3h,i} Meanwhile, the Nicolini group and Liu group reported a copper-catalyzed process with the combination of 1,2-diaza-1,3-diene and diazo ester providing ester-substituted dihydropyrazole.^{3l,m} Therefore, exploring a mild and metal-free method to achieve indoline-2-carboxylic acid and dihydropyrazole carboxylic acid skeletons is still desirable.

The α -halo carbonyl compound has been proven as an attractive C1 partner for the construction of cyclopropane, oxirane, or other cyclic compounds.⁴ An N-containing five-membered compound could be obtained with an α -halo carbonyl compound as the C2 partner via the annulation reaction.⁵ Recently, the α -halo carbonyl was successfully used as the C3 partner to construct heterocyclic compounds with amine, an indole derivative, and alkene.⁶ However, α -halo carbonyl compounds are rarely employed in the [4 + 1] annulation of azoalkene due to the presence of other side reactions. Indeed, in 2019, Chen and co-workers developed a unique [4 + 1 + 1] annulation between α -bromo carbonyls and benzofuran-derived azadiene which offered the fused benzo-aza-heterocycle (Scheme 1a).⁷ Moreover, Zhao's group used indanone-derived or benzofuran-derived azadiene as the starting material to react with bromomalonate, providing the cyclopropane product (Scheme 1b).⁸ A similar strategy was also used by Yang and co-workers to access spiro-cyclopropane indole derivatives (Scheme 1c).⁹ In all of the results mentioned




Figure 1. Biologically active molecules with a dihydropyrazole (A–C) and indoline skeleton (D–F).


Received: July 1, 2022

Accepted: October 12, 2022

Published: November 1, 2022



Scheme 1. Annulation Pathways between Azoalkenes and α -Halo Carbonyl Compounds



above, the [4 + 1] annulation product could not be detected, which demonstrated the challenge of [4 + 1] annulation between azoalkene and α -halo carbonyl compounds. Due to our previous successes in the exploration of the transformation of azoalkene intermediates,¹⁰ we hypothesized that the [4 + 1] annulation would occur between the azoalkene intermediate and α -halo carbonyl compound, providing a metal- and organocatalysis-free protocol to obtain the functionalized dihydropyrazole and indoline derivative (Scheme 1d). Achievement of such a reaction is particularly challenging because: (1) the potential competing dimerization of the azoalkene intermediate leads to an eight-membered N-containing heterocycle;^{10b,11} (2) the construction of the quaternary carbon center in the product is difficult;¹² and (3) the lower leaving ability of Br may suppress the occurrence of the [4 + 1] cycloaddition reaction.

RESULTS AND DISCUSSION

We initially treated α -halo hydrazone (2a) with KOH in the presence of diethyl 2-bromomalonate (1a) in CH₂Cl₂ at room temperature. To our delight, the [4 + 1] cycloaddition product dihydropyrazole 3a was isolated in 58% yield, which was identified through NMR data and confirmed by the X-ray crystallographic analysis of 3e.¹³ Then, several other bases were screened with the aim to improve the yield of cycloaddition product 3a. These results indicated that (1) all other screened bases were better than KOH except triethylamine (TEA) and triethylenediamine (TEDA) (Table 1, entries 1–8); (2) among the different bases, K₂CO₃ was proven to be the best one for this transformation (Table 1, entry 3); and (3) the type of base had an unignorable influence comparing the promotion effect of inorganic base and organic base on this reaction (Table 1, entries 7–8). Using K₂CO₃ as the base, various solvents have been evaluated. We found that this reaction in THF afforded 3a in 89% yield (Table 1, entry 9), while other solvents including CHCl₃, MeCN, DMF, Et₂O,


Table 1. Optimization of Reaction Conditions^a

entry	base	solvent	yield (%) ^b
1	KOH	CH ₂ Cl ₂	58
2	Cs ₂ CO ₃	CH ₂ Cl ₂	62
3	K ₂ CO ₃	CH ₂ Cl ₂	81
4	Na ₂ CO ₃	CH ₂ Cl ₂	72
5	NaHCO ₃	CH ₂ Cl ₂	75
6	KO ^t Bu	CH ₂ Cl ₂	68
7	TEDA	CH ₂ Cl ₂	trace
8	TEA	CH ₂ Cl ₂	trace
9	K ₂ CO ₃	THF	89
10	K ₂ CO ₃	CHCl ₃	76
11	K ₂ CO ₃	MeCN	77
12	K ₂ CO ₃	DMF	63
13	K ₂ CO ₃	Et ₂ O	86
14	K ₂ CO ₃	EtOAc	43
15 ^c	K ₂ CO ₃	THF	56
16 ^d	K ₂ CO ₃	THF	86

^aReaction conditions: 1a (0.15 mmol), 2a (0.1 mmol), and base (0.2 mmol) were reacted at room temperature. ^bIsolated yield based on 2a. ^cReaction was performed at 0 °C. ^dReaction was performed at 70 °C.

and EtOAc were not as good as THF (Table 1, entries 10–14). Subsequent research showed that the temperature had little influence on the efficiency of this transformation (Table 1, entries 15–16). For example, elevated temperature to 70 °C led to the formation of 3a in 86% yield, while decreasing the temperature to 0 °C generated the product in 56% yield. Based on the above screening results, we thus obtained these optimal reaction conditions for this transformation: using K₂CO₃ as the base and THF as the solvent while stirring the reaction mixture at room temperature.

With the optimized conditions in hand, the reaction compatibility was then explored, and these results were summarized in Table 2. The variation of α -halo hydrazone was tested first. When the azoalkene precursor bearing an electron-withdrawing group at the 4-position of the benzene ring was examined, each of the transformations underwent smooth, leading to the formation of the expected product in good yield (3b–3e). However, the fluorine group at the 4-position furnished the product 3f in lower yield. The possible reason is that the strong electron-withdrawing force affects the reactivity of the azoalkene intermediate. As anticipated, α -halo hydrazone having a 3-chlorophenyl group and a 3-bromophenyl group could also provide a similar cyclization process toward dihydropyrazole 3g and 3h in 81% and 85% yields, respectively. Delightedly, the 3,4-disubstituted azoalkene precursor was compatible in this annulation. Moreover, substrates containing an electron-donating (e.g., methyl) group at the *para*-position proved to be effective as well, which provided the corresponding dihydropyrazole 3j with comparable efficiency. In addition, the ether functional group was well-tolerated with this annulation system (3k). However, the *tert*-butyl-substituted azoalkene precursor seemed to be less reactive and achieved 3l in relatively lower yield. To our delight, a sterically encumbered naphthalen-2-yl counterpart

Table 2. Scope with Various α -Halogeno Hydrazone and α -Bromocarbonyl^a

^aReaction conditions: **1** (0.15 mmol), **2** (0.1 mmol), and K_2CO_3 (0.2 mmol) were reacted at room temperature. ^bIsolated yield based on **2**.

was found to be a suitable partner, giving the product **3m** in 80% yield. Next, we investigated the transformation of *N*-acetyl hydrazone with dimethyl malonate. These results indicated that aromatic-substituted, fused-ring-substituted, and alkyl-substituted hydrazones could be smoothly converted into their dihydropyrazole derivatives in 72–84% yields (**3n**, **3o**, and **3p**). Besides, other malonates such as dibenzyl 2-bromomalonate and diisopropyl 2-bromomalonate were all successfully tolerated and offered the expected products **3q** and **3r**. However, the yield was decreased to 54% when diisopropyl 2-bromomalonate was used as the starting material. We reasoned that the steric hindrance has a significant impact on this transformation. Notably, the C1 synthon is not restricted only to the malonate compound, but instead, the bromide of ethyl acetoacetate was also a suitable substrate for this transformation, and the corresponding annulation products (**3s**, **3t**) were isolated in 83% and 60% yields, respectively. When 3-

bromopentane-2,4-dione was used as the starting material, **3u** was obtained in moderate yield.

To further demonstrate the effectiveness of this method, we turned our attention to checking other azoalkene precursors such as **4a** which was used as the four-unit intermediate. Thus, **4a** was reacted with diethyl 2-bromomalonate **1a** under the standard conditions. Delightedly, the desired annulation product **5a** was observed in 26% yield. Next, we optimized the reaction conditions. A higher yield (65%) was obtained after the base screening (Table 3, entries 1–4). Subsequent

Table 3. Optimization of Reaction Conditions for Indoline 5a^a


entry	base	solvent	yield (%) ^b
1	K_2CO_3	THF	26
2	Cs_2CO_3	THF	65
3	$KOtBu$	THF	31
4	Na_2CO_3	THF	52
5	Cs_2CO_3	CH_2Cl_2	77
6	Cs_2CO_3	CH_3CN	74
7	Cs_2CO_3	Et_2O	48

^aReaction conditions: **1a** (0.15 mmol), **4a** (0.1 mmol), and base (0.2 mmol) were reacted at room temperature. ^bIsolated yield based on **4a**.

solvent screening indicated it was more efficient when CH_2Cl_2 was used as the solvent, which delivered product **5a** in 77% yield (entries 5–7). Finally, it was decided to carry out the cyclization process by using Cs_2CO_3 as the base and CH_2Cl_2 as the solvent.


Next, the substrate scope of azoalkene precursor **4** was carefully studied under the optimized conditions. Some salient results were summarized in Table 4. Initially, we focused on the scope of the benzene ring. These results showed that the azoalkene precursor with electron-withdrawing property seemed to be more reactive. *N*-(2-(Chloromethyl) phenyl) benzamide **4** having F and CF_3 substitutes at the 3-position were converted to the corresponding azoalkene intermediates which then underwent [4 + 1] annulation, affording the desired products in better yield (Table 4, **5b** and **5c**). Moreover, the electron-withdrawing groups at the 2-position and 4-position of the benzene ring were tolerated well and provided indoline derivatives **5d** and **5e** in moderate to good yield. The use of an electron-donating substituted azoalkene precursor offered the expected product **5f** in good yield (63%) as well. Furthermore, a functionalized azoalkene intermediate with ether could also be used as the reaction partner to access the corresponding product **5g** in 71% yield. The *tert*-butoxycarbonyl-protected azoalkene precursor was also used in this reaction, and the product **5a** was obtained in 50% yield. In addition, the protecting group was not only limited to benzoyl (Bz) and *tert*-butoxycarbonyl (Boc). The annulation of *N*-benzyloxyformyl (Cbz) azoalkene precursors with C1 synthon **1a** under the optimized conditions also furnished the corresponding products **5i**–**5k** in 68–85% yields.

The synthetic utility of the annulation protocol was then demonstrated by performing these reactions on a gram scale, and these corresponding products **3a** and **5a** were isolated in 86% and 74% yield on a 4 mmol scale, respectively (Scheme

Table 4. Scope with the Azoalkene Precursor 4^{a,b}

^aReaction conditions: **1** (0.15 mmol), **4** (0.1 mmol), and Cs_2CO_3 (0.2 mmol) were reacted at room temperature. ^bIsolated yield based on **4**.

2a,b). Next, these late-stage transformations of product **3a** were conducted. As shown in Scheme 2c,d, the selective


Scheme 2. Gram-Scale Reactions and the Transformation of **3a** and **5h**

reduction of dihydropyrazole **3a** was realized with NaBH_4 in CH_3OH by controlling the temperature. **3a-1** was afforded in 92% yield at room temperature. While the reaction was run at 40 °C, the double reduction product with two hydroxyl groups **3a-2** was delivered in 73% yield (Scheme 2d). Besides, the protected indoline compound could offer the 2-carboxylate

indoline derivative **5-1** under the catalysis of trifluoroacetic acid.

According to our previous studies and the literature,¹⁰ we proposed the following annulation mechanism (Scheme 3).

Scheme 3. Proposed [4 + 1] Annulation Mechanism



These azoalkene intermediates were generated in situ via precursors **2a** and **4a** under the base conditions. Meanwhile, deprotonation of **1** formed the nucleophilic intermediate INT 1. Then, the 1,4-conjugate addition occurred between the INT 1 and azoalkene intermediates, offering INT 2 and INT 3. Subsequently, intramolecular cyclization through the simultaneous C–N and C–C bond formations offered [4 + 1] annulation products **3a** and **5a**.

CONCLUSIONS

In summary, we have successfully developed a metal-free annulation protocol between α -bromocarboxyl compound **1** and α -halo hydrazone **2** or azoalkene precursor **4** to construct the skeletally diverse aza-heterocycle with a quaternary carbon center under mild conditions. Moreover, this approach has a general substrate scope for both the α -bromocarboxyl reagent and α -halo hydrazone or azoalkene precursor **4** with an electron-donating and electron-withdrawing group on the aromatic ring. Furthermore, this transformation developed a method for selective construction of a hydroxyl functional group in the dihydropyrazole compound.

EXPERIMENTAL SECTION

General Information. The ^1H and ^{13}C NMR spectra were recorded on a 400 MHz spectrometer with chloroform-*d* and dimethyl sulfoxide-*d*₆ as the solvent. High-resolution mass spectra (HRMS) were recorded on an FT-ICR MS spectrometer. Melting points are uncorrected. Column chromatography was performed on silica gel (200–300 mesh). α -Bromocarboxyl compound **1** and azoalkene precursors **2** and **4** were synthesized according to literature methods.¹⁴

General Procedure for the Preparation of Dihydropyrazole **3.** To a stirred solution of these α -bromocarboxyl compounds **1** (0.15 mmol) and K_2CO_3 (0.2 mmol) in THF (2 mL) at room temperature was added azoalkene precursor **2** (0.1 mmol). After the reaction was completed, as indicated by TLC, the mixture was concentrated in vacuo, and the crude product was purified by flash chromatography, eluting with ethyl acetate/petroleum ether = 1:20 to afford the product **3**.

Diethyl 2-Acetyl-5-phenyl-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3a**).** Ethyl acetate/petroleum ether = 1:20 was used as an eluent. White solid (30 mg, 89%). MP: 56.3–58.6 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.74–7.66 (m, 2H), 7.45–7.37 (m, 3H), 4.32–4.25 (m, 4H), 3.83 (s, 2H), 2.43 (s,

3H), 1.30 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.06, 167.66, 151.94, 130.74, 130.47, 128.90, 126.70, 72.07, 62.95, 44.29, 21.92, 14.02. HRMS (ESI): m/z calcd for $\text{C}_{17}\text{H}_{21}\text{N}_2\text{O}_5$ $[\text{M} + \text{H}]^+$: 333.1445, found 333.1449.

Diethyl 2-Acetyl-5-(4-cyanophenyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3b). Ethyl acetate/petroleum ether = 1:15 was used as an eluent. White solid (31 mg, 87%). MP: 54.7–55.5 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.79 (d, $J = 8.4$ Hz, 2H), 7.70 (d, $J = 8.4$ Hz, 2H), 4.29 (qd, $J = 7.2, 2.8$ Hz, 4H), 3.81 (s, 2H), 2.43 (s, 3H), 1.30 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.14, 167.34, 149.91, 134.69, 132.63, 127.12, 118.33, 113.84, 72.41, 63.16, 43.86, 21.92, 14.00. HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{19}\text{N}_3\text{NaO}_5$ $[\text{M} + \text{Na}]^+$: 380.1217, found 380.1218.

Diethyl 2-Acetyl-5-(4-chlorophenyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3c). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (31 mg, 85%). MP: 53.9–55.2 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.63 (d, $J = 8.3$ Hz, 2H), 7.39 (d, $J = 8.3$ Hz, 2H), 4.30 (dq, $J = 7.1, 4.2$ Hz, 4H), 3.80 (s, 2H), 2.42 (s, 3H), 1.31 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.94, 167.48, 150.72, 136.65, 129.10, 128.90, 127.84, 72.10, 62.94, 44.05, 21.82, 13.92. HRMS (ESI): m/z calcd for $\text{C}_{17}\text{H}_{19}\text{ClN}_2\text{NaO}_5$ $[\text{M} + \text{Na}]^+$: 389.0875, found 389.0871.

Diethyl 2-Acetyl-5-(4-bromophenyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3d). Ethyl acetate/petroleum ether = 1:20 was used as an eluent. White solid (36 mg, 88%). MP: 61.2–63.4 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.55 (s, 4H), 4.30 (qd, $J = 7.1, 2.7$ Hz, 4H), 3.79 (s, 2H), 2.42 (s, 3H), 1.31 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.06, 167.59, 150.91, 132.18, 129.48, 128.16, 125.14, 72.24, 63.07, 44.13, 21.95, 14.05. HRMS (ESI): m/z calcd for $\text{C}_{17}\text{H}_{19}\text{BrN}_2\text{NaO}_5$ $[\text{M} + \text{Na}]^+$: 433.0370, found 433.0378.

Diethyl 2-Acetyl-5-(4-nitrophenyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3e). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (31 mg, 82%). MP: 62.7–64.3 °C. ^1H NMR (400 MHz, CDCl_3): δ 8.27 (d, $J = 8.9$ Hz, 2H), 7.85 (d, $J = 8.9$ Hz, 2H), 4.31 (qd, $J = 7.2, 2.7$ Hz, 4H), 3.85 (s, 2H), 2.45 (s, 3H), 1.32 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.20, 167.33, 149.58, 148.78, 136.48, 127.43, 124.19, 72.54, 63.23, 43.97, 21.96, 14.03. HRMS (ESI): m/z calcd for $\text{C}_{17}\text{H}_{19}\text{N}_3\text{NaO}_7$ $[\text{M} + \text{Na}]^+$: 400.1115, found 400.1114.

Diethyl 2-Acetyl-5-(4-fluorophenyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3f). Ethyl acetate/petroleum ether = 1:15 was used as an eluent. White solid (27 mg, 78%). MP: 48.9–51.7 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.75–7.64 (m, 2H), 7.15–7.08 (m, 2H), 4.34–4.26 (m, 4H), 3.80 (s, 2H), 2.42 (s, 3H), 1.31 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.04, 167.67, 150.95, 128.78 (d, $J = 8.0$ Hz), 126.84, 116.16 (d, $J = 21.0$ Hz), 72.21, 63.05, 44.34, 21.95, 14.06. HRMS (ESI): m/z calcd for $\text{C}_{17}\text{H}_{19}\text{FN}_2\text{NaO}_5$ $[\text{M} + \text{Na}]^+$: 373.1170, found 373.1172.

Diethyl 2-Acetyl-5-(3-chlorophenyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3g). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (30 mg, 81%). MP: 71.3–72.9 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.70 (t, $J = 1.8$ Hz, 1H), 7.54 (dt, $J = 7.5, 1.5$ Hz, 1H), 7.42–7.32 (m, 2H), 4.29 (qd, $J = 7.2, 3.0$ Hz, 4H), 3.79 (s, 2H), 2.43 (s, 3H), 1.31 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.11, 167.50, 150.57, 135.02, 132.26, 130.64, 130.19, 126.66, 124.82, 72.18, 63.06, 44.11, 21.95, 14.03. HRMS (ESI): m/z

calcd for $\text{C}_{17}\text{H}_{19}\text{ClN}_2\text{NaO}_5$ $[\text{M} + \text{Na}]^+$: 389.0875, found 389.0871.

Diethyl 2-Acetyl-5-(3-bromophenyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3h). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (35 mg, 85%). MP: 51.9–54.1 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.85 (t, $J = 1.8$ Hz, 1H), 7.62–7.54 (m, 2H), 7.29 (t, $J = 7.9$ Hz, 1H), 4.30 (qd, $J = 7.1, 2.7$ Hz, 4H), 3.79 (s, 2H), 2.43 (s, 3H), 1.31 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.14, 167.52, 150.46, 133.57, 132.56, 130.44, 129.61, 125.28, 123.10, 72.22, 63.08, 44.12, 21.97, 14.05. HRMS (ESI): m/z calcd for $\text{C}_{17}\text{H}_{19}\text{BrN}_2\text{NaO}_5$ $[\text{M} + \text{Na}]^+$: 433.0370, found 433.0378.

Diethyl 2-Acetyl-5-(3,4-dichlorophenyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3i). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (33 mg, 83%). MP: 56.5–57.2 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.77 (d, $J = 1.8$ Hz, 1H), 7.54–7.47 (m, 2H), 4.30 (qd, $J = 7.2, 2.9$ Hz, 4H), 3.78 (s, 2H), 2.43 (s, 3H), 1.31 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.09, 167.44, 149.70, 134.82, 133.41, 130.96, 130.53, 128.42, 125.75, 72.33, 63.13, 44.01, 21.95, 14.04. HRMS (ESI): m/z calcd for $\text{C}_{17}\text{H}_{18}\text{Cl}_2\text{N}_2\text{NaO}_5$ $[\text{M} + \text{Na}]^+$: 423.0485, found 423.0481.

Diethyl 2-Acetyl-5-(*p*-tolyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3j). Ethyl acetate/petroleum ether = 1:15 was used as an eluent. White solid (26 mg, 76%). MP: 61.3–64.6 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.58 (d, $J = 7.9$ Hz, 2H), 7.22 (d, $J = 7.9$ Hz, 2H), 4.29 (qd, $J = 7.2, 3.0$ Hz, 4H), 3.81 (s, 2H), 2.43 (s, 3H), 2.39 (s, 3H), 1.30 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.02, 167.76, 152.06, 141.16, 129.61, 127.71, 126.68, 72.02, 62.94, 44.37, 21.95, 21.66, 14.05. HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{22}\text{N}_2\text{NaO}_5$ $[\text{M} + \text{Na}]^+$: 369.1421, found 369.1423.

Diethyl 2-Acetyl-5-(4-methoxyphenyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3k). Ethyl acetate/petroleum ether = 1:15 was used as an eluent. White solid (27 mg, 74%). MP: 57.4–58.8 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.67–7.61 (m, 2H), 6.96–6.91 (m, 2H), 4.29 (qd, $J = 7.2, 2.9$ Hz, 4H), 3.85 (s, 3H), 3.80 (s, 2H), 2.42 (s, 3H), 1.30 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.93, 167.83, 161.67, 151.77, 128.38, 123.13, 114.34, 72.04, 62.94, 55.56, 44.41, 21.95, 14.06. HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{22}\text{N}_2\text{NaO}_6$ $[\text{M} + \text{Na}]^+$: 385.1370, found 385.1366.

Diethyl 2-Acetyl-5-(*tert*-butyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3l). Ethyl acetate/petroleum ether = 1:20 was used as an eluent. White solid (22 mg, 69%). MP: 59.6–61.1 °C. ^1H NMR (400 MHz, CDCl_3): δ 4.28 (ddt, $J = 10.1, 7.1, 3.2$ Hz, 4H), 3.41 (s, 2H), 2.31 (s, 3H), 1.29 (t, $J = 7.1$ Hz, 6H), 1.18 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.08, 167.94, 163.49, 72.13, 62.78, 43.65, 34.08, 27.99, 21.80, 14.07. HRMS (ESI): m/z calcd for $\text{C}_{15}\text{H}_{24}\text{N}_2\text{NaO}_5$ $[\text{M} + \text{Na}]^+$: 335.1577, found 335.1576.

Diethyl 2-Acetyl-5-(naphthalen-2-yl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3m). Ethyl acetate/petroleum ether = 1:20 was used as an eluent. White solid (31 mg, 80%). MP: 55.8–58.2 °C. ^1H NMR (400 MHz, CDCl_3): δ 8.00 (dd, $J = 8.7, 1.7$ Hz, 1H), 7.92 (s, 1H), 7.88–7.82 (m, 3H), 7.58–7.50 (m, 2H), 4.35–4.24 (m, 4H), 3.96 (s, 2H), 2.49 (s, 3H), 1.32 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.10, 167.72, 152.00, 134.36, 133.02, 128.77, 128.56, 128.10, 128.02, 127.58, 127.36, 127.00, 123.26, 72.20, 63.01, 44.29, 22.01, 14.07. HRMS (ESI): m/z calcd for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{NaO}_5$ $[\text{M} + \text{Na}]^+$: 405.1421, found 405.1422.

Dimethyl 2-Acetyl-5-phenyl-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3n). Ethyl acetate/petroleum ether = 1:20 was used as an eluent. White solid (24 mg, 79%). MP: 50.8–51.9 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.73–7.64 (m, 2H), 7.45–7.37 (m, 3H), 3.84 (s, 2H), 3.83 (s, 6H), 2.43 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 169.14, 168.19, 152.14, 130.82, 130.23, 128.89, 126.69, 71.75, 53.80, 44.43, 21.91. HRMS (ESI): *m/z* calcd for C₁₅H₁₆N₂NaO₅ [M + Na]⁺: 327.0951, found 327.0952.

Dimethyl 2-Acetyl-5-(naphthalen-2-yl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3o). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (29 mg, 84%). MP: 51.2–53.5 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.99 (dd, *J* = 8.7, 1.7 Hz, 1H), 7.92 (s, 1H), 7.89–7.83 (m, 3H), 7.58–7.50 (m, 2H), 3.99 (s, 2H), 3.86 (s, 6H), 2.49 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 169.27, 168.26, 152.26, 134.36, 132.96, 128.79, 128.56, 128.00, 127.86, 127.63, 127.45, 127.01, 123.18, 71.89, 53.89, 44.44, 22.01. HRMS (ESI): *m/z* calcd for C₁₉H₁₈N₂NaO₅ [M + Na]⁺: 377.1108, found 377.1106.

Dimethyl 2-Acetyl-5-(tert-butyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3p). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (21 mg, 72%). MP: 50.6–52.3 °C. ¹H NMR (400 MHz, CDCl₃): δ 3.80 (s, 6H), 3.42 (s, 2H), 2.30 (s, 3H), 1.17 (s, 9H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 169.07, 168.50, 163.74, 71.75, 53.72, 43.73, 34.07, 27.95, 21.78. HRMS (ESI): *m/z* calcd for C₁₃H₂₀N₂NaO₅ [M + Na]⁺: 307.1264, found 307.1260.

Dibenzyl 2-Acetyl-5-(tert-butyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3q). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (33 mg, 76%). MP: 49.6–51.2 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.31–7.21 (m, 10H), 5.19 (dd, *J* = 12, 2.3 Hz, 4H), 3.35 (s, 2H), 2.30 (s, 3H), 1.09 (s, 9H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 169.14, 167.51, 163.41, 135.05, 128.56, 128.39, 128.12, 72.00, 68.22, 43.58, 33.96, 27.81, 21.68. HRMS (ESI): *m/z* calcd for C₂₅H₂₈N₂NaO₅ [M + Na]⁺: 459.1890, found 459.1897.

Diisopropyl 2-Acetyl-5-(tert-butyl)-2,4-dihydro-3H-pyrazole-3,3-dicarboxylate (3r). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (19 mg, 54%). MP: 56.4–58.2 °C. ¹H NMR (400 MHz, CDCl₃): δ 5.07–5.01 (m, 2H), 3.32 (s, 2H), 2.24 (s, 3H), 1.21 (dd, *J* = 13.2, 6.3 Hz, 12H), 1.11 (s, 9H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.88, 167.11, 163.16, 72.26, 70.38, 43.34, 33.83, 27.71, 21.59, 21.51, 21.33. HRMS (ESI): *m/z* calcd for C₁₇H₂₈N₂NaO₅ [M + Na]⁺: 363.1890, found 363.1892.

Ethyl 1,5-Diacetyl-3-phenyl-4,5-dihydro-1H-pyrazole-5-carboxylate (3s). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (25 mg, 83%). MP: 64.2–65.6 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.72–7.69 (m, 2H), 7.49–7.26 (m, 3H), 4.26 (qd, *J* = 7.2, 3.0 Hz, 2H), 3.91 (d, *J* = 17.6 Hz, 1H), 3.59 (d, *J* = 17.7 Hz, 1H), 2.46 (s, 3H), 2.45 (s, 3H), 1.30 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 130.92, 128.94, 126.82, 62.87, 43.17, 27.78, 22.04, 14.08. HRMS (ESI): *m/z* calcd for C₁₆H₁₈N₂NaO₄ [M + Na]⁺: 325.1159, found 325.1153.

Ethyl 1,5-Diacetyl-3-(tert-butyl)-4,5-dihydro-1H-pyrazole-5-carboxylate (3t). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (17 mg, 60%). MP: 62.5–63.2 °C. ¹H NMR (400 MHz, CDCl₃): δ 4.27 (qd, *J* = 10.7, 7.1 Hz, 2H), 3.52 (d, *J* = 17.7 Hz, 1H), 3.15 (d, *J* = 17.7 Hz, 1H), 2.40 (s, 3H), 2.32 (s, 3H), 1.28 (t, *J* = 7.1 Hz, 3H), 1.18 (s, 9H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 201.24, 169.34, 168.69,

164.90, 76.07, 62.63, 42.25, 34.13, 27.92, 27.67, 21.86, 14.03. HRMS (ESI): *m/z* calcd for C₁₄H₂₃N₂O₄ [M + H]⁺: 283.1652, found 283.1659.

1,1',1''-(3-Phenyl-4,5-dihydro-1H-pyrazole-1,5,5-triyl)tris(ethan-1-one) (3u). Ethyl acetate/petroleum ether = 1:15 was used as an eluent. White solid (21 mg, 77%). MP: 56.7–59.1 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.70–7.64 (m, 2H), 7.44–7.36 (m, 3H), 3.60 (s, 2H), 2.44 (s, 3H), 2.27 (s, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 202.14, 169.87, 153.82, 131.06, 129.95, 128.88, 126.78, 81.06, 77.48, 77.16, 76.84, 41.64, 26.90, 22.00. HRMS (ESI): *m/z* calcd for C₁₅H₁₇N₂O₃ [M + H]⁺: 273.1234, found 273.1238.

General Procedure for the Preparation of Indoline 5.

To a stirred solution of the α-bromocarbonyl compound **1** (0.15 mmol) and Cs₂CO₃ (0.2 mmol) in dichloromethane (DCM) (2 mL) at room temperature, azoalkene precursor **4** (0.1 mmol) was added. After the reaction was completed, as indicated by TLC, the mixture was concentrated in vacuo, and the crude product was purified by flash chromatography by eluting with ethyl acetate/petroleum ether = 1:10 to afford the product **5**.

Diethyl 1-Benzoylindoline-2,2-dicarboxylate (5a). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (29 mg, 77%). MP: 123.1–125.2 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.60–7.52 (m, 2H), 7.52–7.46 (m, 1H), 7.45–7.37 (m, 2H), 7.12 (d, *J* = 7.4 Hz, 1H), 6.88 (t, *J* = 7.4 Hz, 1H), 6.84–6.77 (m, 1H), 5.92 (d, *J* = 8.2 Hz, 1H), 4.26 (qd, *J* = 7.1, 2.7 Hz, 4H), 3.70 (s, 2H), 1.26 (t, *J* = 7.2 Hz, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.24, 167.85, 141.05, 135.40, 130.91, 128.66, 128.36, 127.34, 127.19, 124.84, 123.52, 114.68, 74.93, 62.30, 38.73, 13.84. HRMS (ESI): *m/z* calcd for C₂₁H₂₁NNaO₅ [M + Na]⁺: 390.1312, found 390.1315.

Diethyl 1-Benzoyl-6-(trifluoromethyl) Indoline-2,2-dicarboxylate (5b). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (36 mg, 82%). MP: 127.9–129.4 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.61–7.52 (m, 3H), 7.52–7.46 (m, 2H), 7.26 (d, *J* = 8.0 Hz, 1H), 7.18 (d, *J* = 7.8 Hz, 1H), 6.09 (s, 1H), 4.36–4.28 (m, 4H), 3.77 (s, 2H), 1.32 (td, *J* = 7.1, 1.0 Hz, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.58, 167.79, 141.84, 134.81, 132.49 (d, *J* = 1.3 Hz), 131.61, 129.98 (d, *J* = 32.3 Hz), 129.14, 127.41, 125.32, 123.56 (d, *J* = 272.4 Hz), 120.67 (q, *J* = 3.9 Hz), 111.78 (q, *J* = 4.2 Hz), 75.21, 62.86, 38.76, 14.05. HRMS (ESI): *m/z* calcd for C₂₂H₂₀F₃NNaO₅ [M + Na]⁺: 458.1186, found 458.1181.

Diethyl 1-Benzoyl-6-fluoroindoline-2,2-dicarboxylate (5c). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (33 mg, 84%). MP: 125.6–127.8 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.60–7.52 (m, 3H), 7.49–7.44 (m, 2H), 7.08–7.04 (m, 1H), 6.61 (td, *J* = 8.5, 2.3 Hz, 1H), 5.62 (dd, *J* = 10.4, 2.2 Hz, 1H), 4.30 (qd, *J* = 7.1, 2.9 Hz, 4H), 3.66 (s, 2H), 1.29 (t, *J* = 7.1 Hz, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.54, 167.88, 162.03 (d, *J* = 243.7 Hz), 142.61 (d, *J* = 11.6 Hz), 135.01, 131.52, 129.07, 127.51, 125.64 (d, *J* = 9.9 Hz), 123.90 (d, *J* = 2.6 Hz), 110.34 (d, *J* = 23.0 Hz), 103.26 (d, *J* = 29.5 Hz), 75.89, 62.71, 38.27, 14.06. HRMS (ESI): *m/z* calcd for C₂₁H₂₀FNNaO₅ [M + Na]⁺: 408.1218, found 408.1214.

Diethyl 1-Benzoyl-5-bromoindoline-2,2-dicarboxylate (5d). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (36 mg, 81%). MP: 123.4–125.9 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.59–7.51 (m, 3H), 7.47–7.42 (m, 2H), 7.29–7.27 (m, 1H), 6.97 (dd, *J* = 8.7, 2.1 Hz, 1H),

5.81 (d, $J = 8.6$ Hz, 1H), 4.31 (qd, $J = 7.1$, 3.4 Hz, 4H), 3.71 (s, 2H), 1.31 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.39, 167.80, 140.58, 135.11, 131.41, 130.86, 130.37, 129.02, 128.07, 127.62, 116.27, 116.25, 75.31, 62.79, 38.60, 14.08. HRMS (ESI): m/z calcd for $\text{C}_{21}\text{H}_{20}\text{BrNNaO}_5$ [$\text{M} + \text{Na}$] $^+$: 468.0417, found 468.0411.

Diethyl 1-Benzoyl-7-chlorindoline-2,2-dicarboxylate (5e). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (30 mg, 74%). MP: 126.5–128.7 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.59–7.51 (m, 3H), 7.46 (dd, $J = 8.7$, 6.6 Hz, 2H), 7.04 (d, $J = 8.0$ Hz, 1H), 6.87 (dd, $J = 8.0$, 1.8 Hz, 1H), 5.85 (d, $J = 1.8$ Hz, 1H), 4.28 (qd, $J = 7.1$, 2.0 Hz, 4H), 3.65 (s, 2H), 1.28 (t, $J = 7.2$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.45, 167.76, 142.39, 134.85, 133.02, 131.51, 129.01, 127.43, 126.99, 125.70, 123.65, 115.31, 75.47, 62.69, 38.39, 13.99. HRMS (ESI): m/z calcd for $\text{C}_{21}\text{H}_{20}\text{ClNNaO}_5$ [$\text{M} + \text{Na}$] $^+$: 424.0922, found 424.0926.

Diethyl 1-Benzoyl-6,7-dimethylindoline-2,2-dicarboxylate (5f). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (25 mg, 63%). MP: 121.7–123.5 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.64–7.51 (m, 2H), 7.42 (t, $J = 7.5$ Hz, 1H), 7.33–7.26 (m, 2H), 6.97 (d, $J = 7.5$ Hz, 1H), 6.86 (d, $J = 7.5$ Hz, 1H), 4.29–4.15 (m, 4H), 3.81 (s, 2H), 2.04 (s, 3H), 1.40 (s, 3H), 1.24 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.39, 141.43, 137.23, 135.93, 131.37, 128.78, 128.21, 127.62, 126.53, 125.20, 121.53, 78.64, 62.56, 40.21, 20.00, 16.57, 13.96. HRMS (ESI): m/z calcd for $\text{C}_{23}\text{H}_{25}\text{NNaO}_5$ [$\text{M} + \text{Na}$] $^+$: 418.1625, found 418.1624.

Diethyl 1-Benzoyl-6-methoxyindoline-2,2-dicarboxylate (5g). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (28 mg, 71%). MP: 120.9–123.3 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.62–7.56 (m, 2H), 7.56–7.43 (m, 3H), 7.01 (dd, $J = 8.3$, 1.0 Hz, 1H), 6.46 (dd, $J = 8.3$, 2.3 Hz, 1H), 5.49 (d, $J = 2.2$ Hz, 1H), 4.30 (qd, $J = 7.2$, 2.4 Hz, 4H), 3.64 (s, 2H), 3.38 (s, 3H), 1.30 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.71, 152.51, 141.61, 135.49, 133.64, 128.61, 128.50, 128.36, 125.02, 124.54, 112.72, 67.73, 62.50, 39.38, 18.49, 13.89. HRMS (ESI): m/z calcd for $\text{C}_{22}\text{H}_{23}\text{NNaO}_6$ [$\text{M} + \text{Na}$] $^+$: 420.1418, found 420.1422.

1-(tert-Butyl) 2,2-Diethyl Indoline-1,2,2-tricarboxylate (5h). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (18 mg, 50%). MP: 128.7–129.9 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 7.80 (s, 1H), 7.26–7.15 (m, 2H), 6.99 (t, $J = 7.4$ Hz, 1H), 4.19 (q, $J = 7.2$ Hz, 4H), 3.62 (s, 2H), 1.40 (s, 9H), 1.20 (t, $J = 7.3$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO}-d_6$): δ 168.39, 128.34, 124.93, 123.35, 114.48, 81.98, 73.39, 62.46, 27.96, 14.26. HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{25}\text{NNaO}_6$ [$\text{M} + \text{Na}$] $^+$: 386.1574, found 386.1569.

1-Benzyl 2,2-Diethyl Indoline-1,2,2-tricarboxylate (5i). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (34 mg, 85%). MP: 106.3–107.4 °C. ^1H NMR (400 MHz, CDCl_3): δ 8.01 (d, $J = 8.2$ Hz, 1H), 7.52–7.09 (m, 7H), 6.98 (d, $J = 7.8$ Hz, 1H), 5.28 (d, $J = 60.2$ Hz, 2H), 4.28–3.96 (m, 4H), 3.69 (s, 2H), 1.26–1.02 (m, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.49, 162.31, 152.43, 141.80, 135.40, 128.44, 128.30, 128.18, 126.15, 124.01, 123.35, 115.17, 73.81, 67.70, 62.41, 40.16, 13.79. HRMS (ESI): m/z calcd for $\text{C}_{22}\text{H}_{23}\text{NNaO}_6$ [$\text{M} + \text{H}$] $^+$: 398.1598, found 398.1591.

1-Benzyl 2,2-Diethyl 7-Methylindoline-1,2,2-tricarboxylate (5j). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (25 mg, 60%). MP: 99.7–102.1 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.42–7.31 (m, 5H), 7.05–6.96

(m, 3H), 5.24 (s, 2H), 4.11 (qq, $J = 7.3$, 3.6 Hz, 4H), 3.77 (s, 2H), 2.27 (s, 3H), 1.18 (t, $J = 7.1$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.63, 152.26, 139.69, 135.53, 131.01, 129.22, 128.46, 128.24, 128.18, 126.90, 124.62, 121.46, 75.95, 67.79, 62.48, 40.30, 20.76, 13.86. HRMS (ESI): m/z calcd for $\text{C}_{23}\text{H}_{25}\text{NNaO}_6$ [$\text{M} + \text{Na}$] $^+$: 434.1574, found 434.1578.

1-Benzyl 2,2-Diethyl 4-Methylindoline-1,2,2-tricarboxylate (5k). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (29 mg, 70%). MP: 97.3–98.8 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.86 (d, $J = 8.1$ Hz, 1H), 7.50–7.31 (m, 5H), 7.21–7.08 (m, 1H), 6.85 (d, $J = 7.8$ Hz, 1H), 5.41–5.18 (m, 2H), 4.30–3.98 (m, 4H), 3.63 (s, 2H), 2.21 (s, 3H), 1.30–1.08 (m, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.48, 168.15, 159.18, 142.38, 135.68, 131.12, 128.94, 127.69, 125.29, 120.45, 109.82, 101.51, 75.88, 62.62, 55.10, 38.34, 29.82, 14.12. HRMS (ESI): m/z calcd for $\text{C}_{23}\text{H}_{25}\text{NNaO}_6$ [$\text{M} + \text{Na}$] $^+$: 434.1574, found 434.1577.

General Procedure for the Preparation of 3a-1. To a stirred solution of the compound 3a (0.1 mmol) in MeOH (2 mL) at room temperature was added NaBH_4 (1 mmol). After the reaction was completed as indicated by the TLC, the mixture was concentrated in vacuo, and the crude product was purified by flash chromatography eluting with ethyl acetate/petroleum ether = 1:10 to afford the products 3a-1 in 92% yield.

Ethyl 1-Acetyl-5-(hydroxymethyl)-3-phenyl-4,5-dihydro-1H-pyrazole-5-carboxylate (3a-1). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. White solid (27 mg, 92%). MP: 93.4–96.5 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 7.78–7.71 (m, 2H), 7.50–7.43 (m, 3H), 5.12 (t, $J = 7.8$ Hz, 1H), 4.18 (dd, $J = 11.5$, 5.7 Hz, 1H), 4.14–4.05 (m, 2H), 3.69 (dd, $J = 11.5$, 6.8 Hz, 1H), 3.63–3.48 (m, 2H), 2.27 (s, 3H), 1.13 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO}-d_6$): δ 170.32, 168.24, 152.77, 131.05, 130.75, 129.23, 126.90, 70.19, 61.33, 61.05, 41.86, 22.23, 14.33. HRMS (ESI): m/z calcd for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{NaO}_4$ [$\text{M} + \text{Na}$] $^+$: 313.1159, found 313.1158.

General Procedure for the Preparation of 3a-2. To a stirred solution of the compound 3a (0.1 mmol) in MeOH (2 mL) at room temperature was added NaBH_4 (1 mmol). Then, the mixture was heated to 40 °C. After the reaction was completed as indicated by TLC, the mixture was concentrated in vacuo, and the crude product was purified by flash chromatography eluting with ethyl acetate/petroleum ether = 1:4 to afford the product 3a-2 in 73% yield.

1-(5,5-Bis(hydroxymethyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl) ethan-1-one (3a-2). Ethyl acetate/petroleum ether = 1:4 was used as an eluent. White solid (18 mg, 73%). MP: 112.4–114.6 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 7.74–7.70 (m, 2H), 7.48–7.42 (m, 3H), 4.99 (s, 2H), 3.98 (d, $J = 11.0$ Hz, 2H), 3.52 (d, $J = 11.0$ Hz, 2H), 3.34 (s, 2H), 2.25 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO}-d_6$): δ 168.87, 152.87, 131.55, 129.96, 128.76, 126.27, 72.80, 61.04, 23.16. HRMS (ESI): m/z calcd for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{NaO}_3$ [$\text{M} + \text{Na}$] $^+$: 271.1053, found 271.1055.

General Procedure for the Preparation of 5-1. To a stirred solution of compound 5h (0.2 mmol) in dichloromethane (2 mL) at 0 °C was added trifluoroacetic acid (TFA) (2 mmol). Then, the mixture was heated to 30 °C. After the reaction was completed, as indicated by TLC, the mixture was concentrated in vacuo, and the crude product was purified by flash chromatography eluting with ethyl acetate/petroleum ether = 1:10 to afford the product 5-1 in 91% yield.

2-(Ethoxycarbonyl) Indoline-2-carboxylic Acid (5-1). Ethyl acetate/petroleum ether = 1:10 was used as an eluent. Colorless oil liquid (43 mg, 91%). ^1H NMR (400 MHz, CDCl_3): δ 9.15 (s, 1H), 7.26 (td, $J = 7.7, 1.4$ Hz, 1H), 7.20 (d, $J = 7.5$ Hz, 1H), 7.08 (td, $J = 7.5, 1.1$ Hz, 1H), 6.92 (dd, $J = 7.9, 1.2$ Hz, 1H), 4.34 (q, $J = 7.1$ Hz, 2H), 3.97 (d, $J = 16.6$ Hz, 1H), 3.40 (d, $J = 16.6$ Hz, 1H), 1.31 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 166.56, 165.13, 135.92, 128.50, 128.29, 124.19, 120.88, 115.95, 63.80, 58.50, 39.90, 14.05. HRMS (ESI): m/z calcd for $\text{C}_{12}\text{H}_{13}\text{NNaO}_4$ [$\text{M} + \text{Na}$] $^+$: 258.0737, found 258.0739.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsomega.2c04127>.

^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra for all of the products (PDF)

AUTHOR INFORMATION

Corresponding Authors

Xiaoke Zhang – Central Laboratory, Chongqing University FuLing Hospital, Chongqing 408000, P.R. China; Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China; orcid.org/0000-0003-0423-5790; Email: xiaokezhang53@163.com

Chaoyong Wang – Central Laboratory, Chongqing University FuLing Hospital, Chongqing 408000, P.R. China; Email: cqwchy@sina.com

Authors

Haibo Wang – Zhejiang Hongyuan Pharmaceutical Co., Ltd., Chem & APIs, Taizhou 310001 Zhejiang, P.R. China

Ziwei Li – Central Laboratory, Chongqing University FuLing Hospital, Chongqing 408000, P.R. China

Yan Shu – Central Laboratory, Chongqing University FuLing Hospital, Chongqing 408000, P.R. China

Song Gan – Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China

Xuefang Zhang – Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China

Huawu Shao – Natural Products Research Centre, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 100045, P.R. China

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acsomega.2c04127>

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We are grateful for financial support from the Youth Science & Technology Personal Growth Project of the Educational Department of Guizhou Province (KY [2021] 227), the Guizhou Province Science and Technology plan program of China (QKHPTRC [2019]-034), CK-1187-029 and Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau) (2020FYYX189).

REFERENCES

- (1) (a) Silva, V. L. M.; Elguero, J.; Silva, A. M. S. Current progress on antioxidants incorporating the pyrazole core. *Eur. J. Med. Chem.* **2018**, *156*, 394. (b) Korablina, D. D.; Vorozhtsov, N. I.; Sviridova, L. A.; Kalenikova, E. I.; Medvedev, O. S. Pharmacological Activity of 4,5-Dihydropyrazole Derivatives. *Pharm. Chem. J.* **2016**, *50*, 281. (c) Marella, A.; Rahmat Ali, M.; Tauquir Alam, M.; Saha, R.; Tanwar, O.; Akhter, M.; Shaquiquzzaman, M.; Mumtaz Alam, M. Pyrazolines: A Biological Review. *MiniRev. Med. Chem.* **2013**, *13*, 921. (d) Blair, L. M.; Sperry, J. Natural Products Containing a Nitrogen–Nitrogen Bond. *J. Nat. Prod.* **2013**, *76*, 794. (e) Zhang, D.; Song, H.; Qin, Y. Total Synthesis of Indoline Alkaloids: A Cyclopropanation Strategy. *Acc. Chem. Res.* **2011**, *44*, 447.
- (2) (a) Harris, P. A.; Faucher, N.; George, N.; Eidam, P. M.; King, B. W.; White, G. V.; Anderson, N. A.; Bandyopadhyay, D.; Beal, A. M.; Beneton, V.; Berger, S. B.; Campobasso, N.; Campos, S.; Capriotti, C. A.; Cox, J. A.; Daugan, A.; Donche, F.; Fouchet, M. H.; Finger, J. N.; Geddes, B.; Gough, P. J.; Grondin, P.; Hoffman, B. L.; Hoffman, S. J.; Hutchinson, S. E.; Jeong, J. U.; Jigorel, E.; Lamoureux, P.; Leister, L. K.; Lich, J. D.; Mahajan, M. K.; Meslamani, J.; Mosley, J. E.; Nagilla, R.; Nassau, P. M.; Ng, S. L.; Ouellette, M. T.; Pasikanti, K. K.; Potvain, F.; Reilly, M. A.; Rivera, E. J.; Sautet, S.; Schaeffer, M. C.; Sehon, C. A.; Sun, H.; Thorpe, J. H.; Totoritis, R. D.; Ward, P.; Wellaway, N.; Wisnoski, D. D.; Woolven, J. M.; Bertin, J.; Marquis, R. W. Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase. *J. Med. Chem.* **2019**, *62* (10), 5096. (b) Joshi, G.; Sharma, M.; Kalra, S.; Gavande, N. S.; Singh, S.; Kumar, R. Design, synthesis, biological evaluation of 3,5-diaryl-4,5-dihydro-1H-pyrazole carbaldehydes as non-purine xanthine oxidase inhibitors: Tracing the anticancer mechanism via xanthine oxidase inhibition. *Bioorg. Chem.* **2021**, *107*, 104620. (c) Salgin-Goksen, U.; Telli, G.; Dedecengiz, E.; Tel, B. C.; Kaynak, F. B.; Yelekci, K.; Ucar, G.; Gokhan-Kelekci, N. New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors. *J. Med. Chem.* **2021**, *64* (4), 1989. (d) Bhirud, J. D.; Patil, R. D.; Narkhede, H. P. Sulfamic acid catalyzed synthesis of new 3,5-[(sub)phenyl]-1H-pyrazole bearing N^1 -isonicotinoyl: And their pharmacological activity evaluation. *Bioorg. Med. Chem. Lett.* **2020**, *30*, 127558. (e) Li, C. L.; Wu, S. C.; Han, G. Y.; Tu, J.; Dong, G. Q.; Liu, N.; Sheng, C. Q. Targeting fungal virulence factor by small molecules: Structure-based discovery of novel secreted aspartic protease 2 (SAP2) inhibitors. *Eur. J. Med. Chem.* **2020**, *201*, 112515. (f) Lamie, P. F.; Azmey, A. F. Synthesis and biological evaluation of tetrazole derivatives as TNF- α , IL-6 and COX-2 inhibitors with antimicrobial activity: Computational analysis, molecular modeling study and region-specific cyclization using 2D NMR tools. *Bioorg. Chem.* **2019**, *92*, 103301. (g) Deng, X.; Liang, K.; Tong, X.; Ding, M.; Zhou, A.; Xia, C. Copper-Catalyzed Radical Cyclization To Access 3-Hydroxypyrrroloindoline: Biomimetic Synthesis of Protubonine A. *Org. Lett.* **2014**, *16*, 3276.
- (3) For selected examples, see: (a) Hu, S. P.; Du, S. Y.; Yang, Z. G.; Ni, L. F.; Chen, Z. K. Synthesis of Multi-substituted Dihydropyrazoles by Copper-Mediated [4 + 1] Cycloaddition Reaction of *N*-Sulfonylhydrazones and Sulfoxonium Ylides. *Adv. Synth. Catal.* **2019**, *361*, 3124. (b) Wei, Q.; Chen, J. R.; Hu, X. Q.; Yang, X. C.; Lu, B.; Xiao, W. J. Photocatalytic Radical Trifluoromethylation/Cyclization Cascade: Synthesis of CF_3 -Containing Pyrazolines and Isoxazolines. *Org. Lett.* **2015**, *17* (18), 4464. (c) Zhao, Q. Q.; Hu, X. Q.; Yang, M. N.; Chen, J. R.; Xiao, W. J. A visible-light photocatalytic N-radical cascade of hydrazones for the synthesis of dihydropyrazole-fused benzosultams. *Chem. Commun.* **2016**, *52*, 12749. (d) Yang, M. N.; Yan, D. M.; Zhao, Q. Q.; Chen, J. R.; Xiao, X. J. Synthesis of Dihydropyrazoles via Ligand-Free Pd-Catalyzed Alkene Amino-arylation of Unsaturated Hydrazones with Diaryliodonium Salts. *Org. Lett.* **2017**, *19*, 5208. (e) Hu, X. Q.; Chen, J. R.; Wei, Q.; Liu, F. L.; Deng, Q. H.; Beauchemin, A.; Xiao, W. J. Photocatalytic Generation of N-Centered Hydrazone Radicals: A Strategy for Hydroamination of β,γ -Unsaturated Hydrazones. *Angew. Chem. Int. Ed.*

- 2014, 53, 12163. (f) Musacchio, A. J.; Nguyen, L. Q.; Beard, G. H.; Knowles, R. R. Catalytic Olefin Hydroamination with Ammonium Radical Cations: A Photoredox Method for Direct C–N Bond Formation. *J. Am. Chem. Soc.* **2014**, 136 (35), 12217. (g) Lopes, S. M. M.; Cardoso, A. L.; Lemos, A.; Melo, T. M. V. D. P. Recent Advances in the Chemistry of Conjugated Nitrosoalkenes and Azoalkenes. *Chem. Rev.* **2018**, 118 (23), 11324. (h) Cleghorn, L. A. T.; Albrecht, S.; Stojanovski, L.; Simeons, F. R. J.; Norval, S.; Kime, R.; Collie, I. T.; Rycker, M. D.; Campbell, L.; Hallyburton, I.; Frearson, J. A.; Wyatt, P. G.; Read, K. D.; Gilbert, I. H. Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of *Trypanosoma brucei*. *J. Med. Chem.* **2015**, 58 (19), 7695. (i) Hou, J. W.; Vázquez-González, M.; Fadeev, M.; Liu, X.; Lavi, R.; Willner, I. Catalyzed and Electrochemical Oxidation of L-Tyrosine and L-Phenylalanine to Dopachrome by Nanozymes. *Nano Lett.* **2018**, 18 (6), 4015. (j) Yu, J. M.; Lu, G. P.; Cai, C. Photocatalytic radical cyclization of α -halo hydrazones with β -ketocarboxyls: facile access to substituted dihydropyrazoles. *Chem. Commun.* **2017**, 53, 5342. (k) Wang, Z. Y.; Yang, Y. Z.; Gao, F.; Wang, Z. Y.; Luo, Q.; Fang, L. Synthesis of 5-(Trifluoromethyl) pyrazolines by Formal [4 + 1]-Annulation of Fluorinated Sulfur Ylides and Azoalkenes. *Org. Lett.* **2018**, 20, 934. (l) Attanasi, O. A.; De Crescentini, L.; Favi, G.; Mantellini, F.; Mantenuto, S.; Nicolini, S. Interceptive [4 + 1] Annulation of in Situ Generated 1,2-Diaza-1,3-dienes with Diazo Esters: Direct Access to Substituted Mono-, Bi-, and Tricyclic 4,5-Dihydropyrazoles. *J. Org. Chem.* **2014**, 79 (17), 8331. (m) Chen, B.; Chu, W. D.; Liu, Q. Z. Formal [4 + 1] cycloaddition of in situ generated 1, 2-diaza-1, 3-dienes with diazo esters: facile approaches to dihydropyrazoles containing a quaternary center. *RSC Adv.* **2019**, 9, 1487. (n) Mei, G. J.; Tang, X. W.; Tasdan, Y.; Lu, Y. X. Enantioselective Dearomatization of Indoles by an Azoalkene-Enabled (3 + 2) Reaction: Access to Pyrroloindolines. *Angew. Chem., Int. Ed.* **2020**, 59, 648. (o) Mei, G. J.; Zheng, W. R.; Gonçalves, T. P.; Tang, X. W.; Huang, K. W.; Lu, Y. X. Catalytic Asymmetric Formal [3 + 2] Cycloaddition of Azoalkenes with 3-Vinylindoles: Synthesis of 2,3-Dihydropyrroles. *iScience.* **2020**, 23, 100873.
- (4) For selected examples, see: (a) Wei, P. S.; Wang, M. X.; Xu, D. C.; Xie, J. W. Synthesis of 2,3-Dihydrothieno(2,3-*b*) quinolines and Thieno(2,3-*b*)-quinolines via an Unexpected Domino Aza-MBH/Alkylation/Aldol Reaction. *J. Org. Chem.* **2016**, 81 (3), 1216. (b) Cheng, J.; Li, W. P.; Duan, Y. Q.; Cheng, Y. X.; Yu, S. Y.; Zhu, C. J. Relay Visible-Light Photoredox Catalysis: Synthesis of Pyrazole Derivatives via Formal [4 + 1] Annulation and Aromatization. *Org. Lett.* **2017**, 19 (1), 214. (c) Li, J. P.; Zhao, G. F.; Wang, H. X.; Xie, M. S.; Qu, G. R.; Guo, H. M. Highly Enantioselective Synthesis of Chiral Cyclopropyl Nucleosides via Catalytic Asymmetric Intermolecular Cyclopropanation. *Org. Lett.* **2017**, 19 (24), 6494. (d) Pelliccia, S.; Alfano, A. I.; Luciano, P.; Novellino, E.; Massarotti, A.; Tron, G. C.; Ravelli, D.; Giustiniano, M. Photocatalytic Isocyanide-Based Multi-component Domino Cascade toward the Stereoselective Formation of minofurans. *J. Org. Chem.* **2020**, 85 (4), 1981. (e) Dong, W. H.; Yuan, Y.; Xie, X. M.; Zhang, Z. G. Visible-Light-Driven Dearomatization Reaction toward the Formation of Spiro [4.5] deca-1,6,9-trien-8-ones. *Org. Lett.* **2020**, 22 (2), 528. (f) Sumino, S. H.; Matsumoto, F.; Iwai, T.; Ito, T. Methanofullerene Synthesis via Photogenerated Fullerene Radical Anion Intermediates. *J. Org. Chem.* **2021**, 86 (12), 8500. (g) Wang, J.; Zhang, Q. Y.; Xie, M. S.; Wang, D. C.; Qu, G. R.; Guo, H. M. Cyclization Reaction of Donor–Acceptor Oxiranes with *N*, *N'*-Disubstituted Thioureas: A Domino Process to *trans*-Dihydropyrimidines. *Org. Lett.* **2018**, 20 (20), 6578. (h) Džambaski, Z.; Bondžić, A. M.; Triandafilidi, I.; Kokotos, C. G.; Bondžić, B. P. Organocatalytic, Organic Oxidant Promoted, Enamine C–H Oxidation/Cyclopropanation Reaction. *Adv. Synth. Catal.* **2021**, 363, 4002.
- (5) For selected examples, see: (a) Ba, D.; Chen, Y. H.; Lv, W. W.; Wen, S.; Cheng, G. L. Copper-Catalyzed Three-Component Cascade Michael Addition/Heck-Type Alkylation/Annulation: Accessing Fully Substituted 1,3-Dihydro-2*H*-pyrrol-2-ones. *Org. Lett.* **2019**, 21 (21), 8603. (b) Gockel, S. N.; Buchanan, T. L.; Hull, K. L. Cu-Catalyzed Three-Component Carboamination of Alkenes. *J. Am. Chem. Soc.* **2018**, 140 (1), 58.
- (6) For selected examples, see: (a) Zhang, X. W.; He, Y. H.; Li, J.; Wang, R.; Gu, L. J.; Li, G. P. CO₂/Photoredox-Cocatalyzed Tandem Oxidative Cyclization of α -Bromo Ketones and Amines To Construct Substituted Oxazoles. *J. Org. Chem.* **2019**, 84 (12), 8225. (b) Chatterjee, T.; Cho, J. Y.; Cho, E. J. Synthesis of Substituted Oxazoles by Visible-Light Photocatalysis. *J. Org. Chem.* **2016**, 81 (16), 6995. (c) Choi, S.; Oh, H.; Sim, J.; Yu, E.; Shin, S.; Park, C. M. Metal-Free Synthesis of Indolopyrans and 2,3-Dihydrofurans Based on Tandem Oxidative Cycloaddition. *Org. Lett.* **2020**, 22 (14), 5528. (d) Hirata, G.; Shimada, T.; Nishikata, T. Organo-photoredox-Catalyzed Atom-Transfer Radical Substitution of Alkenes with α -Carbonyl Alkyl Halides. *Org. Lett.* **2020**, 22 (22), 8952.
- (7) Zeng, R.; Shan, C. Y.; Liu, M.; Jiang, K.; Ye, Y.; Liu, T. Y.; Chen, Y. C. [4 + 1] Annulations of α -Bromo Carbonyls and 1-Azadienes toward Fused Benzoazaheterocycles. *Org. Lett.* **2019**, 21 (7), 2312.
- (8) Fang, Q. Y.; Yi, M. H.; Wu, X. X.; Zhao, L. M. Regio- and Diastereoselective Spirocyclopropanation of Benzofuran-Derived Azadienes through 1,4-Addition-Induced Dearomatization Reaction under Mild Conditions. *Org. Lett.* **2020**, 22 (13), 5266.
- (9) Yang, K. C.; Li, J. L.; Li, Q. Z.; Leng, H. J.; Shen, X. D.; Liu, Y.; Zhu, H. P.; Lai, H. Y.; Zhang, X.; Dai, Q. S.; Liu, Y.; Zeng, R.; Zhang, Y. CN109956896, 2019.
- (10) (a) Zhang, X.; Pan, Y.; Liang, P.; Pang, L.; Ma, X.; Jiao, W.; Shao, H. Oxadiazepine Synthesis by Formal [4 + 3] Cycloaddition of *o*-Chloromethyl Arylsulfonamides with Nitrones Promoted by NaHCO₃. *Adv. Synth. Catal.* **2018**, 360, 3015. (b) Zhang, X.; Pan, Y.; Liang, P.; Ma, X.; Jiao, W.; Shao, H. An Effective Method for the Synthesis of 1,3-Dihydro-2*H*-indazoles via *N*-N Bond Formation. *Adv. Synth. Catal.* **2019**, 361, 5552.
- (11) (a) Shelke, A. M.; Suryavanshi, G. Fluoride-Assisted Synthesis of 1,4,5,6-Tetrahydropyridazines via [4 + 2] Cyclodimerization of in Situ-Generated Azoalkenes Followed by a C–N Bond Cleavage. *Org. Lett.* **2016**, 18, 3968. (b) Zhang, Z.; Zhang, L.; Chen, Q.; Lu, T.; Zhou, Q. Synthesis of functionalized tetrahydropyridazines via catalyst-free self [4 + 2] cycloaddition of in situ generated 1,2-diaza-1,3-dienes. *RSC Adv.* **2016**, 6, 61680.
- (12) (a) Aggarwal, V. K.; Harvey, J. N.; Robiette, R. On the Importance of Leaving Group Ability in Reactions of Ammonium, Oxonium, Phosphonium, and Sulfonium Ylides. *Angew. Chem., Int. Ed.* **2005**, 44, 5468. (b) Fu, Y.; Wang, H. J.; Chong, S. S.; Guo, Q. X.; Liu, L. An Extensive Ylide Thermodynamic Stability Scale Predicted by First-Principle Calculations. *J. Org. Chem.* **2009**, 74, 810. (c) Zaugg, H. E.; Chadde, F. E.; Michaels, J. R. Neighboring Group Reactions. VI. Reactions of 3-(*ω*-Haloalkyl)-3-phenyl-2-benzofuranones with Secondary Amines. Trapped Tetrahedral Intermediates in a Carbonyl Addition Reaction. *J. Am. Chem. Soc.* **1962**, 84, 4567.
- (13) CCDC 2013334 contains the supplementary crystallographic data for compound 3e. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
- (14) (a) Tanemura, K.; Suzuki, T.; Nishida, Y.; Satsumabayashi, K.; Horaguchi, T. A Mild and Efficient Procedure for α -bromination of Ketones Using *N*-bromosuccinimide Catalysed by Ammonium Acetate. *Chem. Commun.* **2004**, 470. (b) Chen, J. R.; Dong, W. R.; Candy, M.; Pan, F. F.; Jorres, M.; Bolm, C. Enantioselective Synthesis of Dihydropyrazoles by Formal [4 + 1] Cycloaddition of in Situ-Derived Azoalkenes and Sulfur Ylides. *J. Am. Chem. Soc.* **2012**, 134, 6924. (c) Hu, X. Q.; Chen, J. R.; Gao, S.; Feng, B.; Lu, L. Q.; Xiao, W. J. [4 + 3] Cycloaddition of in situ Generated Azoalkenes with C,*N*-cyclic Azomethineimines: Efficient Synthesis of Tetrazepine Derivatives. *Chem. Commun.* **2013**, 49, 7905. (d) Wagner, A. M.; knezevic, C. E. K.; Wall, J. L.; Sun, V. L.; Buss, J. A.; Allen, L. T.; Wenzel, A. G. A copper(II)-catalyzed, sequential Michael–aldol reaction for the preparation of 1,2-dihydroquinolines. *Tetrahedron Lett.* **2012**, 53, 833. (e) Yang, Q. Q.; Xiao, C.; Lu, L. Q.; An, J.; Tan, F.; Li, B. J.; Xiao, W. J. Synthesis of Indoles through Highly Efficient Cascade Reactions of

Sulfur Ylides and N-(*ortho*-Chloromethyl)aryl Amides. *Angew. Chem., Int. Ed.* **2012**, *51*, 9137.